心肌肌球蛋白抑制剂治疗肥厚型心肌病的研究进展  

Research Progress of Myocardial Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy

作　　者：裴崇哲 PEI Chongzhe(Department of Cardiovascular Medicine,General Hospital of Tianjin Medical University,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院心血管内科,天津300052

出　　处：《中国医药指南》2024年第9期52-54,共3页Guide of China Medicine

摘　　要：临床中,肥厚型心肌病为遗传性心肌病的一种,且较为普遍,其发生与编码肌蛋白质的基因突变存在密切联系,胸痛、晕厥、以及劳力性呼吸困难等均为该疾病的主要表现。上述疾病发生后,若不能采取及时、有效的救治,伴随疾病进一步发展,则会导致恶性心律失常及心源性猝死等,严重威胁患者的身体健康和生命安全。现如今,伴随医学界对肥厚型心肌病在研究方面的不断深入,心肌肌球蛋白抑制剂在临床中得到了应用,通过对肌球蛋白和肌动蛋白间的结合予以抑制,实现肥厚心肌在高收缩性方面的递减,以此达到治疗效果。但上述药物属于一种新型药物,临床中应用的时间较短,关于具体治疗机制方面的研究也较少。鉴于此,本文在肥厚型心肌病的治疗中,通过对心肌肌球蛋白抑制剂的应用开展深入分析与探究,以便能够为临床实践提供更为可靠的参考依据。In clinical practice,hypertrophic cardiomyopathy is a kind of hereditary cardiomyopathy,and is relatively common.Its occurrence is closely related to gene mutations encoding muscle proteins.Chest pain,syncope,and exertional dyspnea are the main manifestations of this disease.After the occurrence of the above diseases,if timely and effective treatment is not taken,with the further development of the disease,it will lead to malignant arrhythmia and sudden cardiac death,etc.,which will pose a serious threat to the health and life safety of patients.Nowadays,with the continuous deepening of the research on hypertrophic cardiomyopathy in the medical field,myocardial myosin inhibitors have been applied in clinical practice.By inhibiting the binding between myosin and actin,the hypertrophic myocardium can decrease in high contractivity,so as to achieve therapeutic effect.However,these drugs belong to a new type of drugs that have been used in clinical practice for a short time,and there are few studies on the specific therapeutic mechanism.In view of this,in the treatment of hypertrophic cardiomyopathy,this paper carried out in-depth analysis and exploration of the application of myocardial myosin inhibitors in order to provide a more reliable reference for clinical practice.

关 键 词：心肌肌球蛋白抑制剂 肥厚型 心肌病 

分 类 号：R542.2[医药卫生—心血管疾病]